For the quarter ended March 2025, Merck (MRK) reported revenue of $15.53 billion, down 1.6% over the same period last year. EPS came in at $2.22, compared to $2.07 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $15.39 billion, representing a surprise of +0.93%. The company delivered an EPS surprise of +3.26%, with the consensus EPS estimate being $2.15.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Merck performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Sales- Oncology- Keytruda - U.S. $4.31 billion versus the four-analyst average estimate of $4.47 billion. The reported number represents a year-over-year change of +4.6%.
- Sales- Oncology- Keytruda - International: $2.90 billion compared to the $3.08 billion average estimate based on four analysts. The reported number represents a change of +2.4% year over year.
- Sales- Oncology- Alliance revenue- Lynparza - U.S. $145 million versus $121.96 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +7.4% change.
- Sales- Oncology- Alliance revenue- Lynparza - International: $168 million versus $178.66 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +7% change.
- Sales- Oncology- Keytruda: $7.21 billion compared to the $7.55 billion average estimate based on four analysts. The reported number represents a change of +3.7% year over year.
- Sales- Hospital Acute Care- Zerbaxa: $70 million compared to the $63.07 million average estimate based on three analysts. The reported number represents a change of +25% year over year.
- Sales- Oncology- Alliance Revenue- Lynparza: $312 million versus the three-analyst average estimate of $300.62 million. The reported number represents a year-over-year change of +6.9%.
- Sales- Oncology- Alliance revenue- Lenvima: $258 million versus the three-analyst average estimate of $234.33 million. The reported number represents a year-over-year change of +1.2%.
- Sales- Hospital Acute Care- Bridion: $441 million compared to the $410.18 million average estimate based on three analysts. The reported number represents a change of +0.2% year over year.
- Sales- Animal health: $1.59 billion versus the three-analyst average estimate of $1.61 billion. The reported number represents a year-over-year change of +5.1%.
- Sales- Hospital Acute Care- Prevymis: $208 million versus $190.69 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +19.5% change.
- Sales- Oncology- Alliance revenue- Reblozyl: $119 million compared to the $101.77 million average estimate based on three analysts. The reported number represents a change of +67.6% year over year.
View all Key Company Metrics for Merck here>>>
Shares of Merck have returned -10.6% over the past month versus the Zacks S&P 500 composite's -5.1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Merck & Co., Inc. (MRK): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
